ÂÜÀòÂÒÂ×

Giacomo Pirovano has extensive work experience in the field of drug development and research. Giacomo is currently employed as the Director of Drug Development at Evergreen Theragnostics since February 2023. Prior to that, they worked at Novartis as a Principal Scientist from May 2021 to February 2023. Before joining Novartis, Giacomo held multiple roles at Memorial Sloan Kettering Cancer Center, including Research Associate from December 2020 to May 2021, and Research Fellow from August 2017 to November 2020. Giacomo also worked as a Research Scientist at the University of Oxford from August 2016 to July 2017.

Giacomo Pirovano's education history includes a Doctor of Philosophy (Ph.D.) degree in Radiation Oncology/Radiobiology from the University of Oxford, which they obtained from 2012 to 2016. Prior to that, they pursued an MSc degree in Software Technology at Robert Gordon University from 2011 to 2012. Giacomo also holds a Master's Degree in Biomedical Physics from Università di Pavia, obtained from 2009 to 2011. Their undergraduate education includes a Bachelor's Degree in Physics from Università degli Studi di Milano-Bicocca, although the start and end years for this degree are not provided.

In addition to their academic degrees, Giacomo Pirovano has obtained two certifications. Giacomo received a certification in Building a Business from the Saïd Business School, University of Oxford, in December 2015. Giacomo also obtained the "Abilitazione Scientifica Nazionale, Professore Universitario di II fascia" certification from the Ministero dell'Istruzione dell'Università e della Ricerca in May 2022.